Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.41 |
| ▸ | MANBA | O00462 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16282667 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL18463823 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL21765449 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL24558370 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL21924361 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL24849486 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL21103713 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL22748686 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL20855308 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL29398809 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3650044-A1 | ANTI-GLYCAN VACCINES | ETH Zürich (CH) | 2020-05-13 | — | — | EP | claimed |
| EP-3650044-A1 | ANTI-GLYCAN VACCINES | ETH Zürich (CH) | 2020-05-13 | — | — | EP | disclosed |